Biden Says Considering Starting Booster Shots Earlier - Bloomberg
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Japan Suspends 1 Million Doses of Moderna (MRNA) Vaccine as 2 People Die After Receiving Shots
August 30, 2021 10:49 AM EDTThe health ministry of Japan temporarily suspended one more million doses of Moderna's (NASDAQ: MRNA) COVID-19 vaccine after foreign substances were found and two persons died after receiving shots from affected lots.
Japan is grappling with the worst wave of coronavirus in the country yet more than 25,000 were infected with... More
Pfizer (PFE) Announces Positive Results from Phase 3 JADE DARE Trial Comparing the Efficacy of Abrocitinib and Dupilumab for Moderate to Severe Atopic Dermatitis
August 30, 2021 6:46 AM EDTPfizer Inc. (NYSE: PFE) today announced that JADE DARE (B7451050), a 26-week, randomized, double-blind, double-dummy, active-controlled, multi-center Phase 3 study, met its co-primary and key secondary efficacy endpoints. The study showed that abrocitinib was statistically superior compared to dupilumab in each evaluated efficacy measure and had a safety profile consistent with previous studies. The head-to-head study was... More
